How India Can Lead the Global Shift in API Self-Reliance Amid Tariff Pressures
How India Can Lead the Global Shift in API Self-Reliance Amid Tariff Pressures
This article is authored by Ms Shivani Wagh, Joint Managing Director, Supriya Lifescience Ltd
This article is authored by Ms Shivani Wagh, Joint Managing Director, Supriya Lifescience Ltd
Union Budget 2025: Strengthening Healthcare and Pharma Sectors!
The Union Budget 2025 unveils transformative measures for the Healthcare and Pharma sectors, focusing on infrastructure, education, and affordability.
The Union Budget 2025 unveils transformative measures for the Healthcare and Pharma sectors, focusing on infrastructure, education, and affordability.
Pharma stock under Rs 55 in focus as company reports a 38.1 per cent revenue surge & 39.07 per cent jump in PAT
From Rs 43.42 per share (52-week low) to Rs 50.40 per share, the stock is up by 16 per cent.
From Rs 43.42 per share (52-week low) to Rs 50.40 per share, the stock is up by 16 per cent.
Recommendation from Pharmaceuticals Sector
The Indian pharmaceuticals industry plays a prominent role in the global pharmaceuticals arena.
This column gives you a scrip chosen by the research team during the fortnight that is fundamentally strong and expected to give good capital appreciation over a time period of 1 year.
Is The Pharmaceutical Industry Shaping Up To Be The New IT?
US Drug Shortages and India’s Competitive Advantage
Given the shared traits between the pharmaceutical and IT industries,
Special Feature On Pharmaceutical & Healthcare Industry
Keeping Good Health
The corona virus pandemic drew everyone's attention to the need for basic medical facilities across the country, elevating the pharmaceutical and healthcare industries and compelling the government to pay greater attention to them. Mandar Wagh describes how being a major participant in terms of both volume and value globally, the government's emphasis and initiatives all contribute to the success of the industry
Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?
Advent is expected to buy 51 per cent of the promoter’s stake in the company and launch an open offer for an additional 26 per cent
The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of its portfolio company
This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?
The company is ranked among the world’s top 100 biopharmaceutical companies and among the world’s top 50 companies in the off-patent sector.
Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses
This pharma company to acquire a franchise from Glenmark Pharmaceuticals for Rs 313.7 crore
Shares of the company surged more than 1.80 per cent.
Shares of the company surged more than 1.80 per cent.
This pharma company stock went 8 per cent high, do you own it?
With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.
This pharma company stock went 8 per cent high, do you own it? With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.
Upcoming collaboration: Two leading pharma company stocks to watch out for
US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns
Upcoming collaboration: Two leading pharma company stocks to watch out for US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns.
Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!
The board of the company also has recommended a dividend of Rs 1.10 per equity share for the financial year ended March 31, 2022.
The shares of Shilpa Medicare soared 10.47 per cent to Rs 453.25 on BSE after the company announced promising results for the quarter that ended on March 31, 2022.